Association between anti-TNF-α therapy and interstitial lung disease.

ABSTRACT:

Background

Anti-tumor necrosis factor-α (TNF-α) agents have been hypothesized to increase the risk of interstitial lung disease (ILD), including its most severe manifestation, pulmonary fibrosis.

Methods

We conducted a cohort study among autoimmune disease patients who were members of Kaiser Permanente Northern California, 1998-2007. We obtained therapies from pharmacy data and diagnoses of ILD from review of X-ray and computed tomography reports. We compared new users of anti-TNF-α agents to new users of non-biologic therapies using Cox proportional hazards analysis to adjust for baseline propensity scores and time-varying use of glucocorticoids. We also made head-to-head comparisons between anti-TNF-α agents.

Results

Among the 8417 persons included in the analysis,

SUBMITTER: Herrinton LJ 

PROVIDER: S-EPMC3618622 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature